Replimune Group Inc (NASDAQ: REPL) is 17.67% higher on its value in year-to-date trading and has touched a low of $4.92 and a high of $22.21 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The REPL stock was last observed hovering at around $8.64 in the last trading session, with the day’s gains setting it 1.28%.
Currently trading at $9.92, the stock is 15.97% and 37.80% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.84 million and changing 14.81% at the moment leaves the stock 8.49% off its SMA200. REPL registered -52.69% loss for a year compared to 6-month loss of 6.55%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 10.22% gain in the last 1 month and extending the period to 3 months gives it a 42.53%, and is 22.62% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.07% over the week and 8.81% over the month.
Replimune Group Inc (REPL) has around 331 employees, a market worth around $609.29M and $0.00M in sales. Distance from 52-week low is 101.63% and -55.34% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.33%).
The EPS is expected to grow by 0.78% this year
The shares outstanding are 61.42M, and float is at 45.36M with Short Float at 12.65%.
Replimune Group Inc (REPL) Insider Activity
The most recent transaction is an insider sale by Xynos Konstantinos, the company’s Chief Medical Officer. SEC filings show that Xynos Konstantinos sold 15,881 shares of the company’s common stock on Jun 07 ’24 at a price of $7.50 per share for a total of $0.12 million. Following the sale, the insider now owns 0.12 million shares.
Replimune Group Inc disclosed in a document filed with the SEC on May 16 ’24 that Astley-Sparke Philip (Executive Chairman) sold a total of 37,928 shares of the company’s common stock. The trade occurred on May 16 ’24 and was made at $6.47 per share for $0.25 million. Following the transaction, the insider now directly holds 1.49 million shares of the REPL stock.
Still, SEC filings show that on May 16 ’24, Patel Sushil (Chief Executive Officer) disposed off 20,194 shares at an average price of $6.47 for $0.13 million. The insider now directly holds 212,014 shares of Replimune Group Inc (REPL).
